Cleared Special

K263054 - BIOFIRE Respiratory Panel 2.1 (RP2.1)

K263054 is an FDA 510(k) clearance for BIOFIRE Respiratory Panel 2.1 (RP2.1), manufactured by Biofire Diagnostics. The device is a Class 2 Microbiology device with product code QOF cleared through the Special 510(k) pathway after a 21-day FDA review.

K263054 · Biofire Diagnostics · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2026
Decision
21d
Days
Class 2
Risk

K263054 is an FDA 510(k) clearance for the BIOFIRE Respiratory Panel 2.1 (RP2.1). Classified as Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents (product code QOF), Class II - Special Controls.

Submitted by Biofire Diagnostics (Salt Lake City, US). The FDA issued a Cleared decision on September 22, 2026 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3981 - the FDA microbiology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Biofire Diagnostics devices

FDA 510(k) Submission Details - K263054

510(k) Number K263054 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 01, 2026
Decision Date September 22, 2026
Days to Decision 21 days
Submission Type Special
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
81d faster than avg
Panel avg: 102d · This submission: 21d
Pathway characteristics
Modification to existing cleared device.

QOF Device Classification - Class 2, Special Controls

Product Code QOF Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3981
Definition A Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The Sars-cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-target Test Is An In Vitro Diagnostic Device Intended For The Detection And Identification Of Sars-cov-2 And Other Microbial Agents When In A Multi-target Test In Human Clinical Respiratory Specimens From Patients Suspected Of Respiratory Infection Who Are At Risk For Exposure Or Who May Have Been Exposed To These Agents. The Device Is Intended To Aid In The Diagnosis Of Respiratory Infection In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data Or Other Risk Factors.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - QOF Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents

All 35
Devices cleared under the same product code (QOF) and FDA review panel - the closest regulatory comparables to K263054.
Xpert Xpress CoV-2/Flu plus
K263120 · Cepheid · Oct 2026
Xpert Respiratory Panel
K261336 · Cepheid · Sep 2026
FINDER Flu A&B/SARS-CoV-2 Test
K261837 · Baebies, Inc. · Sep 2026
Fast PCR Mini Respiratory Panel
K252932 · Autonomous Medical Devices Incorporated · Jun 2026
VELO Respiratory Test
K251742 · Lex Diagnostics Limited · Feb 2026
LIAISON NES FLU A/B, RSV & COVID-19
K251978 · Diasorin Molecular, LLC · Dec 2025